LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Listă Acțiuni・Puma Biotechnology Inc

Puma Biotechnology Inc

Închisă

SectorSănătate

6.98 3.25

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

6.75

Maxim

7.01

Indicatori cheie
By Trading Economics
Venit	-16M -3.8M
Vânzări	-31M 45M
P/E Medie Sector	14.188 49.701
EPS	-0.04
Marjă de profit	-8.375
Angajați	179
EBITDA	-28M -1.3M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-26.58% downside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-37M 347M
Deschiderea anterioară	3.73
Închiderea anterioară	6.98

Sentimentul știrilor

By Acuity

50%

174 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

3.07 / 3.075 Suport & Rezistență

Puma Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

19 mai 2026, 20:36 UTC

Achiziții, Fuziuni, Preluări

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 mai 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 mai 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 mai 2026, 23:28 UTC

Market Talk

Câștiguri

Global Forex and Fixed Income Roundup: Market Talk

19 mai 2026, 23:28 UTC

Market Talk

Câștiguri

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 mai 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19 mai 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 mai 2026, 22:02 UTC

Câștiguri

ZTO Express (Cayman): Di Xu to Resign From Board

19 mai 2026, 22:01 UTC

Câștiguri

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 mai 2026, 22:01 UTC

Câștiguri

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 mai 2026, 22:00 UTC

Câștiguri

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 mai 2026, 21:37 UTC

Câștiguri

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 mai 2026, 21:31 UTC

Achiziții, Fuziuni, Preluări

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 mai 2026, 21:01 UTC

Câștiguri

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 mai 2026, 20:58 UTC

Câștiguri

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 mai 2026, 20:46 UTC

Acțiuni populare

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 mai 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 mai 2026, 20:34 UTC

Câștiguri

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 mai 2026, 20:32 UTC

Câștiguri

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 mai 2026, 20:32 UTC

Câștiguri

James Hardie Industries 4Q EPS 5c >JHX

19 mai 2026, 20:32 UTC

Câștiguri

James Hardie Industries 4Q Sales $1.4B >JHX

19 mai 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Analog Devices to Buy Empower Semiconductor for $1.5B

19 mai 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 mai 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 mai 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 mai 2026, 20:03 UTC

Achiziții, Fuziuni, Preluări

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 mai 2026, 20:03 UTC

Achiziții, Fuziuni, Preluări

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 mai 2026, 20:02 UTC

Achiziții, Fuziuni, Preluări

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 mai 2026, 20:02 UTC

Achiziții, Fuziuni, Preluări

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 mai 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Comparație

Modificare preț

Puma Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

-26.58% jos

Prognoză pe 12 luni

Medie 5 USD -26.58%

Maxim 5 USD

Minim 5 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPuma Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 1 analiști care au acordat evaluări ale acțiunilor Puma Biotechnology Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

3.07 / 3.075Suport & Rezistență

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

174 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.